チカグレロル
参考資料

↑  “P2Y nucleotide receptors: promise of therapeutic applications”. Drug Discovery Today 15 (13–14):  570–8. (July 2010). doi:10.1016/j.drudis.2010.05.011. PMC 2920619. PMID 20594935. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920619/.
1 2  “Assessment Report for Brilique”.  European Medicines Agency (January 2011). 2021年6月12日閲覧。
↑  European Public Assessment Report Possia
↑  “Drug Approval Package: Brilinta (ticagrelor) NDA #022433”.   U.S. Food and Drug Administration (FDA) (22 August 2011). 22 May 2021閲覧。
↑  “アストラゼネカ 抗血小板薬「ブリリンタ®錠60mg/90mg」の国内製造販売承認を取得”. www.astrazeneca.co.jp. 2021年6月12日閲覧。
↑  “A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)”.   clinicaltrials.gov (2021年5月11日). 2021年6月12日閲覧。
1 2 3 4 5  Haberfeld, H, ed (2010) (ドイツ語). Austria-Codex (2010/2011 ed.). Vienna: Österreichischer Apothekerverlag
1 2  Wallentin, Lars; Becker, Richard C.; Budaj, Andrzej; Cannon, Christopher P.; Emanuelsson, Håkan; Held, Claes; Horrow, Jay; Husted, Steen et al. (2009-09-10). “Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes”. New England Journal of Medicine 361 (11):  1045–1057. doi:10.1056/NEJMoa0904327. hdl:2437/95141. ISSN 0028-4793. PMID 19717846. https://doi.org/10.1056/NEJMoa0904327.
↑  Lindholm, Daniel; Varenhorst, Christoph; Cannon, Christopher P; Harrington, Robert A; Himmelmann, Anders; Maya, Juan; Husted, Steen; Steg, Philippe Gabriel et al. (2014-08-14). “Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial”. European Heart Journal 35 (31):  2083–2093. doi:10.1093/eurheartj/ehu160. ISSN 0195-668X. https://doi.org/10.1093/eurheartj/ehu160.
↑  Hong, Sung-Jin; Ahn, Chul-Min; Kim, Jung-Sun; Kim, Byeong-Keuk; Ko, Young-Guk; Choi, Donghoon; Jang, Yangsoo; Hong, Myeong-Ki (2020-10-09). “Effect of ticagrelor monotherapy on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials including 26 143 patients”. European Heart Journal - Cardiovascular Pharmacotherapy (pvaa119). doi:10.1093/ehjcvp/pvaa119. ISSN 2055-6837. https://doi.org/10.1093/ehjcvp/pvaa119.
↑  “Ticagrelor Monograph for Professionals”. Drugs.com (23 October 2020). 22 May 2021閲覧。
↑  “2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)”. European Heart Journal 39 (3):  213–260. (January 2018). doi:10.1093/eurheartj/ehx419. PMID 28886622.
1 2 3  “Ticagrelor versus clopidogrel in patients with acute coronary syndromes”. The New England Journal of Medicine 361 (11):  1045–57. (September 2009). doi:10.1056/NEJMoa0904327. hdl:2437/95141. PMID 19717846.
↑  “Prasugrel versus clopidogrel in patients with acute coronary syndromes”. The New England Journal of Medicine 357 (20):  2001–15. (November 2007). doi:10.1056/NEJMoa0706482. PMID 17982182.
1 2  “Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes”. The New England Journal of Medicine 381 (16):  1524–1534. (October 2019). doi:10.1056/NEJMoa1908973. PMID 31475799.
↑  “2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines”. Journal of the American College of Cardiology 68 (10):  1082–115. (September 2016). doi:10.1016/j.jacc.2016.03.513. PMID 27036918.
↑  “Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack”. The New England Journal of Medicine 375 (1):  35–43. (July 2016). doi:10.1056/NEJMoa1603060. PMID 27160892.
↑  “Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA”. The New England Journal of Medicine 383 (3):  207–217. (July 2020). doi:10.1056/NEJMoa1916870. PMID 32668111.
1 2  “Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial”. The Lancet. Neurology 16 (4):  301–310. (April 2017). doi:10.1016/S1474-4422(17)30038-8. PMID 28238711.
1 2  “Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin”. Stroke 51 (12):  3504–3513. (December 2020). doi:10.1161/STROKEAHA.120.032239. PMC 7678660. PMID 33198608. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678660/.
↑  “Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study”. Platelets 25 (7):  517–25. (November 2014). doi:10.3109/09537104.2013.842965. PMC 4220996. PMID 24127651. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220996/.
↑  “Ticagrelor Reduces Thrombo Inflammatory Markers in Patients with Pneumonia”. JACC. Basic to Translational Science 3 (4):  435–449. (August 2018). doi:10.1016/j.jacbts.2018.05.005. PMC 6115703. PMID 30175268. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6115703/.
1 2  “ブリリンタ錠60mg／ブリリンタ錠90mg 添付文書”. www.info.pmda.go.jp.   PMDA. 2021年6月12日閲覧。
↑  “Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor”. Clinical Pharmacology 5:  67–83. (April 2013). doi:10.2147/cpaa.s41859. PMC 3640601. PMID 23650452. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640601/.
↑  “Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial”. European Heart Journal 32 (23):  2933–44. (December 2011). doi:10.1093/eurheartj/ehr422. PMID 22090660.
1 2 3 4  “Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes”. European Heart Journal 32 (23):  2945–53. (December 2011). doi:10.1093/eurheartj/ehr231. PMID 21804104.
1 2 3  “Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study”. Journal of the American College of Cardiology 56 (3):  185–93. (July 2010). doi:10.1016/j.jacc.2010.01.062. PMID 20620737.
1 2  “Dyspnea in patients treated with P2Y12 receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry”. Platelets 28 (7):  691–697. (November 2017). doi:10.1080/09537104.2016.1265919. PMID 28150522.
↑  “The risk of dyspnea in patients treated with third-generation P2Y12 inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials”. BMC Cardiovascular Disorders 20 (1):  140. (March 2020). doi:10.1186/s12872-020-01419-y. PMC 7079377. PMID 32183711. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079377/.
↑  “The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy”. Journal of the American College of Cardiology 57 (19):  1908–16. (May 2011). doi:10.1016/j.jacc.2010.11.056. PMID 21545948.
↑  6 [リンク切れ]
↑  “Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers”. European Journal of Clinical Pharmacology 69 (3):  477–87. (March 2013). doi:10.1007/s00228-012-1369-4. PMID 22922682.
↑  “Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins”. Drugs 78 (11):  1105–1112. (July 2018). doi:10.1007/s40265-018-0947-x. PMC 6061431. PMID 30003466. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061431/.
↑  “Ticagrelor versus clopidogrel in patients with acute coronary syndromes”. The New England Journal of Medicine 361 (11):  1045–57. (September 2009). doi:10.1056/NEJMoa0904327. hdl:2437/95141. PMID 19717846.
↑  “Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects”. Drug Metabolism and Disposition 38 (9):  1514–21. (September 2010). doi:10.1124/dmd.110.032250. PMID 20551239.
↑  “National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016”. Heart, Lung & Circulation 25 (9):  895–951. (September 2016). doi:10.1016/j.hlc.2016.06.789. PMID 27476580.
↑  “2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)”. European Heart Journal 37 (3):  267–315. (January 2016). doi:10.1093/eurheartj/ehv320. PMID 26320110.
↑  “2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines”. Journal of the American College of Cardiology 64 (24):  e139-e228. (December 2014). doi:10.1016/j.jacc.2014.09.017. PMID 25260718.
↑  “Brilinta (ticagrelor) Prescribing Information”.   AstraZeneca (2019年). 2021年6月12日閲覧。
↑  “Australia Product Information Brilinta (ticagrelor)”.   AstraZeneca (2019年). 2021年6月12日閲覧。
↑  “Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial”. Circulation 124 (5):  544–54. (August 2011). doi:10.1161/CIRCULATIONAHA.111.047498. PMID 21709065.
↑  “Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor”. Journal of Blood Medicine 1:  197–219. (2010). doi:10.2147/JBM.S9650. PMC 3262315. PMID 22282698. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262315/.
↑  “Neue Wirkstoffe - AZD6140” (ドイツ語). Österreichische Apothekerzeitung (3/2008):  135. (February 4, 2008).
↑  “AZD6140”. Drugs of the Future 32 (10):  845–853. (2007). doi:10.1358/dof.2007.032.10.1133832.
↑  [信頼性の低い医学の情報源？] “First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies”. Circulation. Cardiovascular Genetics 3 (6):  556–66. (December 2010). doi:10.1161/CIRCGENETICS.110.958561. PMID 21079055.
↑  “Brilique: EPAR – Product Information”.  European Medicines Agency (2019年10月16日). 2021年6月12日閲覧。
↑  “Is there too much excitement for ticagrelor?”.   TheHeart.org (24 February 2010). 2021年6月12日閲覧。
↑  “Neue Wirkstoffe - Elinogrel” (ドイツ語). Österreichische Apothekerzeitung (2/2011):  10. (17 January 2011).
1 2  [信頼性の低い医学の情報源？] “Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study”. Lancet 375 (9711):  283–93. (January 2010). doi:10.1016/S0140-6736(09)62191-7. PMID 20079528.
↑  [信頼性の低い医学の情報源？] “Ticagrelor versus clopidogrel in patients with acute coronary syndromes”. The New England Journal of Medicine 361 (11):  1045–57. (September 2009). doi:10.1056/NEJMoa0904327. hdl:2437/95141. PMID 19717846.
↑  “Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes”. Core Evidence 6:  31–42. (2011). doi:10.2147/CE.S9510. PMC 3065559. PMID 21468241. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065559/.
↑  “Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?”. Thrombosis and Haemostasis 108 (3):  412–4. (September 2012). doi:10.1160/TH12-04-0251. PMID 22836596.
↑  “Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study”. American Heart Journal 157 (4):  658–65. (April 2009). doi:10.1016/j.ahj.2008.08.031. PMID 19332192.
↑  “Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: Systematic review and meta-analysis”. Cardiovascular Revascularization Medicine 19 (6):  689–694. (September 2018). doi:10.1016/j.carrev.2018.01.009. PMID 29452843.
↑  “Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials”. Journal of Comparative Effectiveness Research 7 (3):  281–291. (March 2018). doi:10.2217/cer-2017-0074. PMID 29094604.
↑  “Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study”. Circulation Journal 79 (11):  2452–60. (2015). doi:10.1253/circj.CJ-15-0112. PMID 26376600.
↑  “Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial”. American Heart Journal 169 (6):  899–905.e1. (June 2015). doi:10.1016/j.ahj.2015.03.015. PMID 26027629.
↑  “Ticagrelor for Asian patients with acute coronary syndrome in real-world practice: A systematic review and meta-analysis of observational studies”. Indian Heart Journal 71 (1):  15–24. (2019). doi:10.1016/j.ihj.2019.01.003. PMC 6477146. PMID 31000178. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477146/.
1 2 3  “Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria”. JAMA Cardiology 4 (6):  596–599. (June 2019). doi:10.1001/jamacardio.2019.1189. PMC 6506905. PMID 31066863. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506905/.
↑  Lupu, Lior; Shepshelovich, Daniel; Banai, Shmuel; Hershkoviz, Rami; Isakov, Ofer (2020-09-01). “Effect of Ticagrelor on Reducing the Risk of Gram-Positive Infections in Patients With Acute Coronary Syndrome” (English). American Journal of Cardiology 130:  56–63. doi:10.1016/j.amjcard.2020.06.016. ISSN 0002-9149. PMID 32680674. https://www.ajconline.org/article/S0002-9149(20)30591-9/abstract.
↑  Butt, Jawad H; Fosbøl, Emil L; Gerds, Thomas A; Iversen, Kasper; Bundgaard, Henning; Bruun, Niels Eske; Larsen, Anders R; Petersen, Andreas et al. (2020-08-04). “Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections”. European Heart Journal - Cardiovascular Pharmacotherapy (pvaa099). doi:10.1093/ehjcvp/pvaa099. ISSN 2055-6837. https://doi.org/10.1093/ehjcvp/pvaa099.